Luveltamab tazevibulin

N/A

Report date: 2025/09/24 20:02:07

Base Information

Drug NameLuveltamab tazevibulin
Drug Alias Nameanti-FolRa ADC STRO-002anti-FolRalpha ADC STRO-002FolR-alpha-ADC (Sutro Biopharma)LuveltaLuxeltamab tazevibulin +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Hemiasterlin analogue payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionFolate receptor alpha antagonists
TargetsFolate receptor alpha
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsFallopian Tube Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[15] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSutro Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesPiramal Pharma Solutions IncSutro Biopharma IncTianjin Tasly Pharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursEndometrial NeoplasmsFallopian Tube Neoplasms +[7] 
Inactive IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsLeukemia, Myeloid, Acute +[4] 

Other Information

ATC CodeN/A
Related LinksN/A